Ablynx Receives Further Milestone Payments Of Eur3 Million ($4.2 Million)

Ablynx Receives Further Milestone Payments Of Eur3 Million ($4.2 Million) As Part Of Its Strategic Alliance With Boehringer Ingelheim Corporation

GHENT, BELGIUM--(Marketwire - October 01, 2010) - Ablynx [Euronext Brussels: ABLX] today announced that it will receive further milestone payments totalling EUR3 million from Boehringer Ingelheim, triggered as part of its strategic alliance for the development and commercialisation of Nanobodies(®). Ablynx has now earned a total of EUR12 million in milestone payments as part of this agreement.

Ablynx and Boehringer Ingelheim entered into an agreement in September 2007 to collaborate on the discovery, development and commercialisation of up to 10 different Nanobody therapeutics across a range of areas including for example immunology, oncology and respiratory diseases. The agreement would allow potential milestone payments of up to EUR125 million for each Nanobody developed as well as undisclosed royalties to Ablynx. Boehringer Ingelheim is exclusively responsible for the development, manufacture and commercialisation of any products resulting from the collaboration. Ablynx retains certain co- promotion rights in Europe.

Dr Edwin Moses, CEO and Chairman of Ablynx, said: "We are pleased that yet another Nanobody programme has reached this contractual milestone. The Nanobody platform continues to deliver across therapeutic areas and also for complex targets."

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.